NSTEMI is considered one of the leading causes of morbidity and mortality and its definition and treatment remains challenging requiring specific, adapted responses. Understanding different biomarkers, becoming aware of emerging new agents used in adjunctive pharmacotherapy, keeping abreast of advances in imaging techniques as well as the use of invasive imaging and functional assessment is critical. Tools, devices and techniques, and complications such as different types of vascular access or bleeding risks, can also be found here.
X
Authors
Tags
Type
Publication year
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)